Trial Information
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Inclusion Criteria:
- Having a new diagnosis of Nasopharyngeal carcinoma.
- Being treated with either radiotherapy or chemoradiotherapy for this condition.
Exclusion Criteria:
- Age <18 since NPC is a very rare condition in this age group and may have a different
biological behavior
- Patients who are unable to provide informed consents for themselves.
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Outcome Measure:
Plasma Epstein-Bar Virus (EBV) DNA concentrations
Outcome Description:
measured by quantitative polymerase chain reaction (PCR)
Outcome Time Frame:
every 6 months until end of study
Safety Issue:
No
Principal Investigator
Quynh-Thu Le
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Institutional Review Board
Study ID:
ENT0006
NCT ID:
NCT00186433
Start Date:
November 2001
Completion Date:
June 2013
Related Keywords:
- Mouth Cancer
- Lip Cancer
- Throat Cancer
- Lip Neoplasms
- Head and Neck Cancers
- Neoplasms
- Carcinoma
- Head and Neck Neoplasms
- Lip Neoplasms
- Mouth Neoplasms
- Nasopharyngeal Neoplasms
Name | Location |
Stanford University School of Medicine |
Stanford, California 94305-5317 |